0001096906-24-000489.txt : 20240318
0001096906-24-000489.hdr.sgml : 20240318
20240318175110
ACCESSION NUMBER: 0001096906-24-000489
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231228
FILED AS OF DATE: 20240318
DATE AS OF CHANGE: 20240318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chinoporos Constantine
CENTRAL INDEX KEY: 0002014509
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38898
FILM NUMBER: 24760350
MAIL ADDRESS:
STREET 1: C/O APPLIED THERAPEUTICS, INC.
STREET 2: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Applied Therapeutics, Inc.
CENTRAL INDEX KEY: 0001697532
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-220-9226
MAIL ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER COMPANY:
FORMER CONFORMED NAME: Applied Therapeutics Inc.
DATE OF NAME CHANGE: 20170208
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2023-12-28
0
0001697532
Applied Therapeutics, Inc.
APLT
0002014509
Chinoporos Constantine
C/O APPLIED THERAPEUTICS, INC.
545 FIFTH AVENUE, SUITE 1400
NEW YORK
NY
10017
0
1
0
0
See Remarks
0
Common Stock
2023-12-28
4
A
0
300000.0000
0.0000
A
300000.0000
D
Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 28, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date.
Chief Operating Officer and Chief Business Officer
/s/ Shoshana Shendelman, as attorney-in-fact
2024-03-18